Occipital Nerve Stimulation in Chronic Migraine
- Conditions
- Chronic Migraine, HeadacheRefractory Migraine
- Registration Number
- NCT07087678
- Lead Sponsor
- University College, London
- Brief Summary
The goal of this clinical trial is to compare two different types of occipital nerve stimulation (BurstDR (dorsal root) microdosing versus Tonic) in chronic refractory migraine. The main questions it aims to answer is whether BurstDR microdosing is effective in reducing moderate to severe headache days compared to Tonic stimulation (which is currently in use). Additionally, the safety of both types of stimulation will be studied.
Participants will be asked to keep a headache diary, then have the device implanted and programmed, and keep a subsequent headache diary to see if there is an improvement in their headaches after three moths of stimulation. If they don't respond to treatment, they will be allowed to swap to the other type of stimulation to see if this improves their symptoms.
- Detailed Description
Eligible subjects will complete a baseline headache diary and questionnaires, and then be randomised to BurstDR microdosing or tonic stimulation. After implantation and stabilisation, the device is activated and they continue to complete headache diary and questionnaires at 1 month, 3 months and 6 months whilst further programming optimisation occurs. Non-responders are offered the opportunity to cross over into the opposite arm. Further diary and questionnaire monitoring will occur at 1 year and optional long term follow up at 2 years.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 40
Age ≥ 18 years old and diagnosed with intractable chronic migraine by a headache specialist, as defined by the International Classification of Headache Disorders-3 (ICHD-3).
Subject should have failed to gain benefit from at least 4 classes of oral preventative medications, Botulinum toxin or acupuncture as defined by NHS (National Health Service) England Subject has been diagnosed at least 6 months prior to study enrolment with migraine headache with or without aura according to the ICHD-3 criteria 1.1, 1.2.1, or 1.3.
Subject is able to distinguish migraine attacks from other headaches (e.g. tension type headache, cluster headaches).
Subject agrees to not participate in supplemental or alternative therapy through the Follow Up Period of the study. This includes acupuncture, spinal manipulation, TENS (transcutaneous electrical nerve stimulation), and magnetic fields treatments.
Subject has the ability to read, comprehend, and to reliably record information as required by the Protocol.
Subject is able to provide written informed consent prior to participation in the study.
Subject's overall health, age and/or comorbidities place subject at high risk for complications from surgery and/or general anaesthesia.
Subject has clinically significant drug (including opioid) or alcohol abuse as defined by DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision), will likely be unable to refrain from substance abuse throughout the study, has another significant pain problem, substance abuse or active depressive episode that might confound the study assessments in the opinion of the Investigator.
Subject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to, an investigational drug or device, except for sponsor-related studies.
Subject is felt to be at risk of non-compliance (e.g., for completing the diary/questionnaires or returning for required follow-up visits) in the Investigator's opinion.
Subject has medication overuse headache which has not been managed (by withdrawal of the causative medication).
Subject is a woman of childbearing potential who is pregnant, nursing, or not using effective contraception.
Subject has an active implantable device such as pacemaker/ defibrillator or other neurostimulation device.
Subject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP (glycoprotein) IIb IIIa inhibitor medication in preparation for the implantation procedure.
Subject is not suitable for the study for any reason in the judgment of the Investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Efficacy of ONS 3 months post activation of ONS The primary objective is to compare the reduction in moderate to severe headache days at three months (i.e. weeks 8-12 post activation of the ONS device) in patients who have tonic stimulation compared to those having BurstDR stimulation.
Severity of headache will be recorded on a 0-10 pain scale in a daily in a headache diary which is completed by the patient throughout the baseline and intervention period.
Moderate to severe headache days are defined as: a 24-hour period with headache pain of moderate or severe intensity that lasts at least 4 hours without medication, or a day with a headache pain of at least moderate intensity that responds to acute treatment with a migraine-specific medication. On the pain scale, 1-3/10 equates to mild pain, 4-6/10 equates to moderate pain and 7-10/10 equates to severe pain.
- Secondary Outcome Measures
Name Time Method Number and severity of adverse events with Tonic and BurstDR stimulation 1,3,6 months compared to baseline Adverse events (AEs) will be recorded for all patients at each follow up appointment (and in between appointments if appropriate).
Each adverse event will be assessed for severity, causality, seriousness and expectedness. AEs will be recored from the time of ONS insertion until the end of the subject's involvement in the trial.
Definitions:
Mild AE: does not interfere with the participant's daily routine, and does not require further intervention; it causes slight discomfort
Moderate AE: interferes with some aspects of the participant's routine, or requires further intervention, but is not damaging to health; it causes moderate discomfort
Severe AE: results in alteration, discomfort or disability which is clearly damaging to health30% responder rate 1,3,6 months compared to baseline The proportion of subjects which achieve ≥30% reduction in headache load at one, three and six months compared to baseline) for tonic verses BurstDR microdosing
Monthly migraine days 1,3,6 months compared to baseline Change in monthly migraine days
Monthly moderate to severe headache days 6,9,12 months post activation Change in monthly moderate to severe headache days compared to baseline
Headache severity 1,3,6 months compared to baseline Change in monthly mean headache severity compared to baseline
The pain scale described in the primary outcome measure will be applied here.Change in mean monthly headache load At 1, 3, 6 months post activation Headache load is calculated as the sum of the product of pain severity (on 0-10 scale), headache duration in hours for each attack over a 28 day period.
A lower headache load equates to a better outcome.HIT-6 score (Headache Impact Test - 6) 1,3 and 6 months post activation Change in mean HIT-6 score compared to baseline
A lower HIT-6 score equates to a better outcome. The minimum value is 36 and the maximum value is 78.MIDAS (migraine disability assessment) score 1,3 and 6 months post activation Change in MIDAS score compared to baseline
A lower score equates to a better outcome. The minimum value is 0 and the maximum value is 270.Hospital anxiety scores (HADS-A) 1,3 and 6 months post activation Change in HADS-A compared to baseline A lower score equates to a better outcome. The minimum score is 0 and the maximum is 21.
Hospital depression score (HADS-D) 1,3 and 6 months post activation Change in HADS-D compared to baseline
A lower score equates to a better outcome. The minimum score is 0 and the maximum is 21.Change in EuroQol-5D5L (European Quality of Life 5 Dimensions) score 1,3,6 months compared to baseline The EuroQol-5D5DL score measures quality of life in dimensions of life activities, and includes a global rating of their overall health.